- Zacks Small Cap Research•3 days ago
On August 17, 2016, InVivo Therapeutics Holdings Corp. (NVIV) announced that patient number nine had converted from a complete AIS A to an incomplete AIS B spinal cord injury in between the second and third month evaluations. This marks the fifth patient to improve at least one AIS grade of eight patients that are currently enrolled in the study. As a result of achieving this milestone, we increase the probability of ultimate FDA approval from 65% to 75% and increase our target price from $16.00 per share to $18.00 per share. To assess probable benefit, InVivo along with the FDA established the objective performance criteria (OPC) in February of this year. The OPC was set at 25% or more of the patients in the INSPIRE study achieving an improvement of at least one AIS grade by six months post-implantation.
- TheStreet.com•7 days ago
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
InVivo Therapeutics Holdings Corp. (NVIV)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
|Bid||6.50 x 2000|
|Ask||8.85 x 700|
|Day's Range||7.07 - 7.35|
|52wk Range||3.50 - 11.80|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-10.90|
|Avg Vol (3m)||222,001|
|Dividend & Yield||N/A (N/A)|